TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third ... NASDAQ ... the company's novel third-generation anti-CD20 monoclonal antibody, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) who were previously treated with rituximab (Rituxan®). This is the company's first clinical trial ... |